Search

Breast cancer (BC) is a diverse disease with heterogeneous subgroups in pathophysiology and behavior. Recent advances in biomarker-based therapy may help improve treatment options for BC. Thus, this study aimed to assess the role of interleukin (IL)-31 and IL-33 as biomarkers associated with BC risk. Serum concentrations of IL-31 and IL-33 were quantified in women with BC (n = 77), women with benign breast lesion (BBL; n = 51), and healthy women (n = 75), using enzyme-linked immunosorbent assay kits. Compared with BBL or healthy women, IL-33 concentrations were significantly greater in BC patients and were associated with a 1.33-fold increased risk of disease and had excellent prognostic value in BC (area under the curve = 0.89). In addition, IL-33 expression was linked to triplenegative BC, distant metastasis, Tumor-Node-Metastasis (TNM) stage, status of estrogen and progesterone receptors, and human epidermal growth factor receptor 2. IL-31 concentrations showed no significant differences between BC, BBL, and healthy women, but were greater in patients with distant metastasis and those who were negative for estrogen and progesterone receptors. In conclusion, IL-33 and to a lesser extent IL-31 can be used as biomarkers associated with BC risk and to identify patients with a poor prognosis especially those with triple-negative BC. Furthermore, understanding the connection between IL-33 and BC progression may aid in the development of safe and effective therapy. [ABSTRACT FROM AUTHOR]

Schizophrenia poses a considerable disease burden, notwithstanding its relatively low incidence rate. The escalation in population size and mean age has led to a substantial rise in the incidence of illness linked to schizophrenia, particularly in countries with moderate levels of prosperity. Therefore, it is necessary to find a way to detect and recognize the illness as fast as possible to stop the consequences from occurring and stop symptoms from appearing before they even start. Within this study’s scope, fifteen distinct primers were selected randomly to determine whether or not they could recognize schizophrenia. To accomplish this, a Randomly Amplified Polymorphic DNA-polymerase chain reaction (RAPD-PCR) was conducted utilizing DNA samples obtained from individuals afflicted with the condition and those in good health. The outcomes of the gel electrophoresis and subsequent analysis revealed that solely three primers including C12, E02 and E03 exhibited monomorphic characteristics. However, it was observed that 80% of the primers, precisely eleven out of fifteen, exhibited polymorphism. The results indicated that among the 15 primers tested, the primer labeled as H01 failed to generate any detectable bands. Subsequent examination of the polymorphic primers revealed that the primer efficiency varied between 0 and 0.0755, while the discrimination power ranged from 0 to 20 percent. The study observed variations in the frequency of disease occurrence between patients and healthy individuals. H05 primer utilization yielded three distinct polymorphic bands exhibiting diverse lengths. The band exhibiting the greatest length measured 1190 bp, whereas the other two bands had 480 and 430 bp lengths respectively. The two polymorphic bands exhibited 100% prevalence in the patient population while being completely absent in the healthy control group. Based on the available data, it appears that utilizing this primer to identify schizophrenia is a valid and valuable claim. Overall, DNA-based diagnostics may overlook a number of difficulties as laboratories have the ability to extract DNA from various sources easily. In this scenario, molecular and genetic techniques may be crucial for diagnosing some diseases. [ABSTRACT FROM AUTHOR]